They say that serum albumin may exert a protecting effect on outcomes in CAP patients by maintaining osmotic pressure and microvascular integrity, transporting hormones such as cortisol and thyroxine, modulating acid-base stability, and inducing antioxidant and anti-apoptotic effects. Certified from medwireNews with authorization from Springer Healthcare Ltd. All privileges reserved. Neither of these ongoing parties endorse or recommend any commercial products, services, or equipment..The effect of the license contract with Merck can be reflected in the business’s revenue and operating expenses for the three – and six-month periods ended June 30, 2010. The Company reported revenue of $175.0 million for the quarter ended June 30, 2010, in comparison with $2.1 million for the same period in 2009 2009, and $177.2 million for the six-month period ended June 30, 2010, when compared with $4.0 million for the same period in 2009 2009. Revenue this year 2010 includes the $50 million up-front payment from Merck and $12.8 million from Merck for reimbursement of ARIAD’s share of the costs related to ridaforolimus for the period from January 1, 2010 to May 4, 2010, the day the restructured contract became effective. Revenue this year 2010 also contains the recognition of up-front and milestone payments previously received from Merck pursuant to the 2007 collaboration agreement, which had been deferred for accounting purposes, amounting to $109.4 million and $111.5 million for the three – and six-month periods ended June 30, 2010, respectively.